Establishing Polymeric Transfection as a Non-Viral, Non-Toxic Method for Gene Therapy in the Prevention of Vascular Disease  by Arnold, Joshua D. et al.
A
m
M
D
T
y
D
t
p
t
r
o
p
h
a
h
s
c
a
a
s
c
i
a
a
a
d
A
r
a
m
A
A
B
R
S
w
o
r
o
(
o
JOURNAL OF VASCULAR SURGERY
December 20111862 AbstractsEstablishing Polymeric Transfection as a Non-Viral, Non-Toxic
Method for Gene Therapy in the Prevention of Vascular Disease
Joshua D. Arnold, Deidra J.H. Mountain, Michael B. Freeman,
Stacy S. Kirkpatrick, Scott L. Stevens, Mitchell H. Goldman,
Oscar H. Grandas, University of Tennessee Graduate School of Medicine,
Knoxville, Tenn
Objective: Gene therapy shows promise in the treatment of vascular
disease, but a formidable challenge has been delivery of genetic material in a
safe and non-toxic way. Traditional transfection methods commonly used in
the laboratory are poorly translatable in vivo, and there are currently no
FDA-approved gene therapy products for clinical application. Biodegrad-
able polymers, particularly poly(B-amino ester)s, have shown promise in
their ability to deliver genetic material to a cell in a predictable and non-toxic
way. However, the preponderance of early feasibility studies were tested and
validated exclusively in stem cells. While stem cell derived therapies are
promising in areas such as vascular tissue engineering and angiogenesis,
dysfunctional regulation in differentiated cells is the primary source of
pathogenesis. As such, gene therapy in these differentiated cell types would
be prime targets for therapeutic gene modulation in the prevention of
hyperplasia and restenosis. Here we aim to establish polymeric transfection
as a feasible non-viral, non-toxic method for gene therapy in cells of vascular
origin and in vascular tissue.
Methods: Human aortic smooth muscle cells (HASMC) were trans-
fected in vitro and rodent carotid artery segments were transfected ex vivo
with poly(-amino ester) polymers (StemFECT™) conjugated to Cy3-
labeled GAPDH or negative control (NC) siRNA. Increasing polymer:
siRNA ratios were tested for optimal transfection efficiency. At 48hrs post-
transfection a live-dead stain was performed to confirm cell/vessel viability,
conjugate endocytosis was confirmed by fluorescent microscopy, and
GAPDH gene silencing was measured by qPCR normalized to 18S.
Results: Cellular translocation of the polymeric bioconjugates in
HASMC in vitro was visible using a 0.65L polymer: 100pmol siRNA/ml
conjugate (Fig 1, A). Efficient gene silencing was achieved in a polymer
concentration dependent manner, independent of increasing siRNA con-
centrations (Fig 1, B). Themost efficient in vitro GAPDH silencing was with
a 1.95L polymer: 100pmol siRNA/ml conjugate (10  1% expression vs
NC; n  5; *P  .05 vs NC and 1.3L:100pmol conjugate). Using this
bioconjugate ratio for vessel transfection ex vivo, translocation was visible in
all cellular layers (Fig 2, B; images representative of proximal, medial, and
distal sections), and modest GAPDH silencing was observed (76  8%
expression vs NC; n  2).
Conclusions: HASMCs and whole vessel segments were successfully
transfected using polymeric bioconjugates. The significant gene silencing
accomplished here establishes our proof of concept that polymeric transfec-
tion is a viable method for in vitro and ex vivo investigation in vascular cells.
Future studies will expand on this method of gene therapy for in vivo
transfection in animal models of vascular disease. Our long term goal is to
deliver molecular inhibitors of genes thought to play a role in intimal
hyperplasia, restenosis, and vessel graft failure. Polymeric transfection may
translate to targeted genetic therapy for vascular disease.
Fig 1. l
wttenuation of Spinal Cord Ischemia-Reperfusion Injury With Treat-
ent of Alpha-2 Agonist Dexmedetomidine
arshall T. Bell, Phillip D. Smith, Joseph C. Cleveland, Jr.,
avid A. Fullerton, Xainzhong Meng, Michael J. Weyant, Ferenc Puskas,
. Brett Reece, Univeristy of Colorado, Aurora, Colo
Background:Despite surgical adjuncts, delayed lower extremity paral-
sis remains a devastating complication following thoracic aortic surgery.
exmedetomidine is a selective -2a agonist commonly used for sedation in
he critical care setting. It has been shown to have both neuronal and renal
rotective affects against ischemia-reperfusion injuries. We hypothesized
hat treatment with dexmedetomidine will attenuate spinal cord ischemia-
eperfusion injury via inhibition of microglial activation.
Methods: Adult C57bL/6 mice underwent sternotomy followed by
cclusion of the aortic arch for 4 minutes. Eight experimental mice received
retreatment with 25ìg/kg of intrapeirtoneal dexmedetomidine and at 12
our intervals following reperfusion. Eight control mice received an equiv-
lent amount of 0.9% normal saline. Functional analysis was obtained at 12
ours intervals and scored using the Basso, Beattie and Bresnahan (BBB)
core until 60 hours. All mice were euthanized at 60 hours. Their spinal
ords were removed en bloc and were stained with hematoxylin and eosin to
sses neuronal viability. Immunofluorescence staining with Iba-1marker a of
ctivated microglia was done at 12 hours after reperfusion in three mice (1
ham, 1 ischemic , control and 1 dexmedetomidine treated).
Results: Treated mice demonstrated preserved motor function as
ompared with ischemic controls (Fig 1). In addition, cyto-architecture in
schemic control mice showed decreased neuronal viability by hematoxylin
nd eosin staining. Immunofluorescence staining of spinal cords at 12 hrs
fter reperfusion with Iba-1, marker of activated microglia, shows decreased
ctivation of microglia in treatment groups.
Conclusions: Treatment of mice with alpha-2 agonist dexmedetomi-
ine preserves motor function after spinal cord ischemia- reperfusion injury.
dditionally, dexmedetomidine preserves spinal cord cyto-architecture and
educes microglia activation. In conclusion dexmedetomidine appears to
ttenuate spinal cord ischemia-reperfusion injury through inhibition of
icroglia activation.
dipose-Derived Stem Cells Versus Artery Explants as Sources of
utologous Smooth Muscle for Blood Vessel Bioengineering
rian W. Bernish, Xue Ma, Zhan Wang, Masood Machingal, Shay Soker,
andolph L. Geary, Wake Forest University School of Medicine, Winston-
alem, NC
Background: Blood vessel bioengineering holds promise for patients
ithout vein suitable for arterial reconstruction or dialysis access but the lack
f a ready source of autologous cells from which to construct new vessels
emains a limitation. We have engineered vessels for use in a pre-clinical
vine model using smooth muscle cells cultured from native artery wall
aSMC) but an artery biopsy is less practical in the clinical setting. A number
f investigators have suggested adipose-derived stem cells (ADSC) provide a
Fig 2.ess invasive alternative source of SMC but methods and results have varied
idely.
